Should Airway Hyper-Responsiveness Be Included in the Definition of Clinical Remission With Biologic Therapy in Severe Asthma

J Allergy Clin Immunol Pract. 2024 Apr;12(4):904-907. doi: 10.1016/j.jaip.2023.12.013. Epub 2023 Dec 12.

Abstract

Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics.

Keywords: Airway hyper-responsiveness; Asthma; Biologic; Remission.

Publication types

  • Review

MeSH terms

  • Asthma* / drug therapy
  • Biological Therapy
  • Humans
  • Inflammation
  • Mannitol / therapeutic use
  • Respiratory Hypersensitivity*

Substances

  • Mannitol